MedTrace Logo

Transcranial Direct Current Stimulation for Hallucinations in First-Episode Schizophrenia

NCT02661347 · Status: WITHDRAWN · Phase: NA · Type: INTERVENTIONAL

Last updated 2018-03-13

No results posted yet for this study

Summary

The purpose of this study is to test the efficacy of transcranial direct current stimulation (tDCS) for the treatment of auditory hallucinations in patients currently on risperidone treatment who are experiencing recent onset psychosis.

Conditions

  • Schizophrenia
  • Schizophreniform
  • Schizoaffective Disorder
  • Psychosis Not Otherwise Specified (NOS)

Interventions

DRUG

Risperidone

The dosage for risperidone will be 1 mg to 6 mg per day. The dose of the risperidone will be based on the participant's clinical improvement and side effects.

DEVICE

tDCS

Transcranial direct current stimulation (tDCS) is a form of non-invasive brain stimulation in which sub-threshold transcranial electric current (in the range of 0.4-2 mA) is applied via two conductive saline soaked electrodes placed on the scalp using a Soterix Medical 1x1 line tDCS Model 1300 low-intensity stimulator.

Sponsors & Collaborators

  • Northwell Health

    lead OTHER

Principal Investigators

  • Deepak Sarpal, M.D. · Northwell Health

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
15 Years
Max Age
40 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2016-02-29
Primary Completion
2016-12-01
Completion
2016-12-01

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02661347 on ClinicalTrials.gov